PURPOSE. CNTF is a neuroprotective agent for retinal degenerations that can cause reduced electroretinogram (ERG) amplitudes. The goal of the present study was to determine the effects of intraocular delivery of CNTF on normal rat visual function. METHODS. Full-field scotopic and photopic ERG amplitudes and spatial frequency thresholds of the optokinetic response (OKR) of adult Long-Evans rats were measured before and after intravitreous injection of CNTF or subretinal delivery of adenoassociated virus-vectored CNTF (AAV-CNTF) into one eye. Visual acuity was also measured by using the Visual Water Task in AAV-CNTF-injected animals. Multiunit luminance thresholds were recorded in the superior colliculus after CNTF injection, and the eyes were examined histologically. RESULTS. In eyes injected with a high dose of CNTF, ERG amplitudes and OKR thresholds measured through CNTF-injected eyes were decreased by 45% to 70% within 6 days after injection. ERG amplitudes had begun to recover by 21 days, whereas OKR thresholds only began to recover after 56 days. Neither OKR thresholds nor ERG amplitudes fully recovered until 90 to 100 days. When measured in the superior colliculus at 2 weeks after CNTF injection, luminance thresholds were elevated by 0.35 log units. In AAV-CNTF-injected eyes, OKR thresholds, and visual acuity were reduced by approximately 50% for at least 6 months, and scotopic and photopic ERG b-waves were reduced by 30% to 50%. Photoreceptor loss occurred in the injected regions in some of the eyes. By contrast, comparison of dose-response analysis with a doseresponse study of light damage strongly suggests that therapeutic doses of CNTF exist that do not suppress ERG responses. CONCLUSIONS. Intraocular delivery of CNTF, which preserves photoreceptors in animal models of retinal degeneration, impairs visual function in normal rats at very high doses, but not at lower doses that still provide protection from constant light damage. (Invest Ophthalmol Vis Sci. 2007;48:5756 -5766 21 and protects PRs from the damaging effects of light in rats 2 and mice. 15 The relative lack of specificity of CNTF in its survival-promoting activity is potentially advantageous and has led, in part, to a recent phase I (safety) clinical trial using implants of encapsulated cells releasing CNTF in patients with retinitis pigmentosa 22 using encapsulated cell technology described previously in the rcd1 canine model of retinitis pigmentosa.
elevated by 0.35 log units. In AAV-CNTF-injected eyes, OKR thresholds, and visual acuity were reduced by approximately 50% for at least 6 months, and scotopic and photopic ERG b-waves were reduced by 30% to 50%. Photoreceptor loss occurred in the injected regions in some of the eyes. By contrast, comparison of dose-response analysis with a doseresponse study of light damage strongly suggests that therapeutic doses of CNTF exist that do not suppress ERG responses. CONCLUSIONS. Intraocular delivery of CNTF, which preserves photoreceptors in animal models of retinal degeneration, impairs visual function in normal rats at very high doses, but not at lower doses that still provide protection from constant light damage. (Invest Ophthalmol Vis Sci. 2007;48:5756 -5766) DOI:10.1167/iovs.07-0054 S everal neuroprotective agents slow photoreceptor (PR) cell loss in animal models of inherited retinal degenerations (RDs). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Ciliary neurotrophic factor (CNTF) appears to be mutation independent and the most universally effective thus far, as it slows PR degeneration in 12 different inherited RDs in mice, 14 -17 rats, 18, 19 dogs (Pearce-Kelling S et al., IOVS 1998; 39:ARVO Abstract 2645) 20 and cats (Chong NHV et al. IOVS 1997; 38 :ARVO Abstract 1445) 21 and protects PRs from the damaging effects of light in rats 2 and mice. 15 The relative lack of specificity of CNTF in its survival-promoting activity is potentially advantageous and has led, in part, to a recent phase I (safety) clinical trial using implants of encapsulated cells releasing CNTF in patients with retinitis pigmentosa 22 using encapsulated cell technology described previously in the rcd1 canine model of retinitis pigmentosa. 20 A worrisome property of CNTF is that, whereas it rescues PRs from degeneration when delivered continuously after adenoassociated virus (AAV) vector transduction, it reduces scotopic (rod-dominated) and photopic (cone-dominated) electroretinographic (ERG) amplitudes, 17, 18 which are typically a measure of PR and retinal function. This effect appears to occur in a dose-dependent manner. 17 The continuous delivery of CNTF also results in a reduction of some or all ERG responses in normal mice, 23 rabbits, 24 and rats (Liang FQ et al. IOVS 2003; 44 :ARVO E-Abstract 3585). Continuous delivery of CNTF has also been associated with structural changes in PRs 17, 24, 25 and inner retinal cells, 25, 26 with outright loss of PR cells in some cases (Liang FQ et al. IOVS 2003; 44 :ARVO E-Abstract 3585), and these changes also appear to occur in a dose-dependent manner in mice (LaVail MM et al., unpublished observations, 2004) . 25 In contrast to continuous delivery, the intravitreous injection of CNTF or Axokine (Regeneron, Tarrytowy, NY), a mutant form of CNTF, has also been shown to reduce ERG amplitudes transiently in dogs with cone-rod dystrophy (Luthert PJ, personal communication, 2001 ) and in normal rats. 27 In both of these cases, the ERG suppression was evident by approximately 1 to 2 weeks after injection (rat and dog, respectively), but at 3 to 4 weeks after injection, the ERG amplitudes had returned to match those of the control eyes in the same animals. In the study with rats, transient changes in PR structure and PR phototransduction proteins also occurred. 27 An important unanswered question about the suppression of ERG responses by CNTF is whether it reflects functional change in vision. In most instances, the reduction of ERG amplitudes follows the loss of vision in patients with inherited RDs, and so the suppression of ERG amplitudes by CNTF may be seen as a negative effect. In some cases, though, reduced or absent ERG amplitudes seem to have little effect on vision, such as in Duchenne muscular dystrophy. 28, 29 Moreover, it is not clear that CNTF-induced ERG alterations are a negative effect, since the agent can, in fact, protect PRs from cell death at the same time as reducing ERG amplitudes. 17, 18, 23 To understand the effect of CNTF-induced reduction of ERG responses on vision in the normal, mature rat eye, we used a virtual optokinetic system (VOS; OptoMotry; CerebralMechanics, Lethbridge, Alberta, Canada 30, 31 ) to quantify spatial frequency thresholds of the optokinetic response (OKR), before and after intravitreous injection of CNTF, which results in transient suppression of ERG responses, and subretinal injection of AAVvectored CNTF, which results in sustained suppression of ERG responses. In addition, we used the Visual Water Task 32 to evaluate the effects of the AAV-vectored CNTF on perceptual spatial vision. The central physiological consequences of CNTF injection were also examined by measurement of luminance thresholds in the superior colliculus. After behavioral testing, the retinas were examined for the morphologic phenotypic features some have found to be associated with the application of CNTF, 17, 24, 25 and the behavioral findings were correlated with measurements of ERG amplitudes.
MATERIALS AND METHODS

Animals and Injections
All studies were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the guidelines of the institutional animal care committees at the University of Lethbridge, University of Utah, and University of California, San Francisco. Adult Long-Evans rats were maintained in a 12:12-hour light-dark cycle at an in-cage illuminance of Ͻ150 lux. Before injections, ERG measurements or physiological recording from the superior colliculus, rats were anesthetized with intramuscular mixture of ketamine (13 mg/kg) and xylazine (87 mg/kg). The corneas were anesthetized with 0.5% proparacaine, and the pupils were dilated with 2.5% phenylephrine hydrochloride followed by 1.0% atropine.
To study transient effects of CNTF, intravitreous monocular injections of recombinant rat CNTF (R&D Systems, Minneapolis, MN) were made using a transscleral approach as described elsewhere, 33 and the dose of 10 g (2 mg/mL in 5 L of PBS) was injected to be consistent with that used previously by Wen et al. 27 After our initial study, we performed a dose-response analysis of the effects of intravitreously injected recombinant rat CNTF at doses of 1000, 100, 10, and 1 ng, each in a volume of 2 L.
For comparison of the dose-response analysis of rat CNTF effects on the ERG responses and OKR thresholds to therapeutic doses of CNTF, we included the morphologic results of a dose-response study of the protective effect of rat CNTF performed several years ago by one of us (MML) in normal albino Sprague-Dawley rats 3 to 4 months of age. The recombinant rat CNTF for this study was a gift of Regeneron Pharmaceuticals and was injected intravitreously into one eye of rats at doses of 400, 200, 100, 50, 25, 10, 2, and 0.2 ng, each in a volume of 1 L. Two days after the injection of CNTF, the rats were exposed to constant fluorescent light for 7 days at an illuminance level of 125 to 175 foot-candles, as described elsewhere. 34 To study long-term effects of constitutively secreted CNTF, we made subretinal injections of AAV-vectored CNTF into the superior hemisphere of rat eyes as described. 17 The AAV vector (serotype 2) with chicken ␤-actin promoter resulted in the expression of a secreted (DH) variant of human CNTF with an increased affinity toward CNTFR␣, 35 which was the most potent survival-promoting form of several AAV-CNTF types in rescuing PRs in rds ϩ/ϪP216L mice. 17 Two microliters of the rAAV-CBA-sDH-CNTF vector (hereafter, AAV-CNTF) with a titer of 10 11 infectious particles per milliliter 17 were injected into one eye of each rat. In initial experiments, we found that both intravitreous and subretinal PBS-injected eyes gave indistinguishable results from noninjected eyes, as measured by histology, ERG, and OKR testing. Therefore, noninjected eyes served as control samples for most of the experimental study.
Electroretinography
The rats were dark-adapted overnight and then, in dim red light, were anesthetized as described earlier. Bilateral, simultaneous, full-field scotopic ERGs were elicited with 10-s flashes of white light, and responses were recorded with contact lens electrodes 36 (UTAS-E 3000 Visual Electrodiagnostic System; LKC Technologies, Inc., Gaithersburg, MD). Scotopic stimuli were presented at an intensity of 0.4 log cd-s/m 2 at 2-minute intervals, and the response to two successive flashes was averaged, followed by a single stimulus at 2.4 log cd-s/m 2 . The rats were then exposed to a background light of 29 cd/m 2 for 10 minutes before photopic responses were recorded to stimuli presented at a rate of 2 Hz at 0.4 log cd-s/m 2 ; 20 successive flashes were averaged. Responses were amplified at a gain of 4000, filtered between 0.3 and 500 Hz, and digitized at a rate of 2000 Hz on two channels. The amplitude of the a-and b-waves was measured. Scotopic a-waves were measured from the baseline to the peak in the cornea-negative direction in response to a stimulus of ϩ2.4 log cd-s/m 2 , and the b-waves were measured from the cornea-negative peak to the major corneapositive peak in response to a stimulus of ϩ0.4 log cd-s/m 2 . ERG responses from the treated eye were compared to responses from the contralateral control eye for each animal.
Virtual Optokinetic System
OKR spatial frequency thresholds were measured once before injection and repeatedly after injection. The VOS measures the threshold of optokinetic tracking response to moving gratings. 30, 31 The apparatus consisted of four computer monitors positioned around a square testing arena. A sine wave grating was drawn on a virtual cylinder projected in three-dimensional coordinate space on the monitors (OptoMotry; CerebralMechanics), and the cylinder was rotated. In brief, an unrestrained rat was placed on a platform in the center of the arena. A video camera provided real-time video feedback from above, and the position of the head on each frame was used to center the hub of the cylinder continually at the rat's viewing position. The cylinder was rotated at a constant speed (12°/s). On each trial an experimenter judged whether the rat made tracking movements with its head and neck to follow the drifting grating. The spatial frequency threshold, the point at which animals no longer tracked, was obtained by incrementally increasing the spatial frequency of the grating at 100% contrast. Thresholds through each eye were measured separately by reversing the rotation of the cylinder.
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Visual Water Task
The visual water task (VWT) is a visual-perception task described elsewhere in detail. [37] [38] [39] [40] Briefly, the apparatus consisted of a trapezoidal-shaped pool with two computer monitors facing through a clear glass wall into the wide end of the pool, and a midline divider extended into the pool from between the monitors, creating a Y-maze with a stem and two arms. Animals were trained to discriminate between a sine wave grating and gray of the same mean luminance displayed on the screens by a computer program (Vista; CerebralMechanics).
Training and testing followed the same procedure as described elsewhere, 37, 38 except the animals were tested only once at approximately 180 days postinjection (PI) of AAV-CNTF. The animals were tested in blocks of trials at progressively incrementing spatial frequencies until they could no longer distinguish between the visual stimuli at a minimum of 7 of 10 correct. Grating acuity was calculated as the 70% correct point on a cumulative normal curve fit to the data. Monocular testing required placing a small occluder over one eye during each trial, which was removed immediately after that trial. All testing was performed early in the light phase of the circadian cycle. Thresholds through each eye were obtained in sequence.
Luminance Threshold Responses Recorded in the Superior Colliculus
We measured luminance thresholds by recording multiunit neuronal responses in the superior colliculus contralateral to the tested eye, as described elsewhere. 41 In short, for each position recorded in the superior colliculus, a discrete receptive field was localized and the brightness of a flashing spot, 3°in diameter projected on a hemisphere, was varied with neutral-density filters until a response was obtained that was double the background activity. This response was defined as the luminance threshold level. The measurements were performed 2 weeks after CNTF injection at the initial high dose of 10 g (2 mg/mL in 5 L of PBS). The luminance thresholds were measured separately in both colliculi, contralateral to treated and untreated eyes in the same animal in one recording session, to compare both eyes in the same individual rat.
Histology and Morphometric Analysis
After behavioral testing, animals received a lethal dose of sodium pentobarbital (Euthansol; Schering-Plough Animal Health, PointeClaire, Quebec, Canada; 0.3 mL/kg), and those killed after ERG testing or constant light exposure were killed with an overdose of carbon dioxide and then were immediately perfusion fixed with a mixture of 2% paraformaldehyde and 2.5% glutaraldehyde in phosphate-buffered saline. Eyes were marked for orientation, removed, and then bisected along the vertical meridian and embedded in an Epon-Araldite mixture, with sections cut at a 1-m thickness as described. 42 Measurements of the outer nuclear layer (ONL) thickness, taken as an index of the number of PRs 43 and rod outer segment lengths, were obtained from 54 locations around the retina as described. 1, 44 These 54 measurements were either averaged to provide a single value for each retina to allow statistical comparison of treatment and control groups or plotted as a distribution of thickness across the retina. For morphologic assessment of the therapeutic dose-response of CNTF in the light-damage experiments, the relative scale of 0 to 4ϩ rescue based on number of PRs surviving and PR integrity was used, as has been described.
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Statistical Analysis
In most cases, the data between CNTF-injected and contralateral control eyes were compared by two-tailed paired Student's t-test. OKR spatial frequency thresholds were compared at each time point for each rat by repeated-measures analysis of variance (ANOVA), with the Bonferroni post hoc test for ANOVA (P Ͻ 0.05) used to compare means at individual time points.
RESULTS
Effects of Intravitreous Injection of CNTF
The most thorough analysis of transient effects of intravitreously injected CNTF is that by Wen et al. 27 To compare our findings with that work, in most of our studies described herein, we used the same large dose of 10 g as was used by Wen et al. 27 These findings are followed by dose-response analyses of CNTF injection.
Functional Changes Measured with the ERG. A group of 11 rats monocularly injected with 10 g CNTF was initially followed for 28 days PI, since we anticipated an initial suppression of maximum ERG amplitudes at 6 days, with full recovery by 21 days PI. 27 Indeed, at 6 days PI, the scotopic a-and b-waves and photopic b-wave amplitudes were 45% to 70% lower than those of their fellow control eyes (Fig. 1A) . However, at 21 and 28 days PI, whereas the scotopic a-waves had recovered to levels not significantly different from those of control eyes, the scotopic b-wave and photopic b-wave amplitudes unexpectedly had not yet fully recovered (Fig. 1A) .
A second group of 7 rats was then followed with weekly ERG recordings from 28 to 98 days PI. Remarkably, each of the ERG amplitudes was suppressed for an extended period (Fig.  1A) . Scotopic a-wave amplitudes remained below control levels throughout most of the test period, although they were significantly different only at 42 and 70 days PI (Fig. 1A) .
FIGURE 1.
Changes in the ERG and spatial frequency thresholds of the OKR after intravitreous injection of 10 g CNTF. (A) Maximum ERG amplitudes of injected eyes compared with those of control eyes measured simultaneously. At 6 days PI, all three waves were 45% to 70% lower than those of control eyes. The maximum amplitudes of each of the ERG waves remained lower than those of control eyes through 91 day PI, with variable degrees of statistical significance. The scotopic a-waves mostly recovered to near normal by 21 days PI, whereas the photopic b-waves recovered the slowest, still significantly different from the control at 81 days PI. At 6 days PI, n ϭ 11 rats; thereafter n ϭ 5 to 7 rats, except at 91 days (n ϭ 4) and 98 days (n ϭ 3). Data are expressed as the mean Ϯ SEM. *P Ͻ 0.05; **P Ͻ 0.01; ***P Ͻ 0.005; ****P Ͻ 0.001; *****P Ͻ 10 Ϫ5 ; those values not marked are not significantly different from the control. (B) OKR spatial frequency thresholds measured through eyes injected intravitreously with 10 g CNTF compared with noninjected control eyes. By 3 days PI, the thresholds declined to approximately 0.450 cyc/deg, where they are already significantly different (P Ͻ 0.001) from the control threshold of 0.53 cyc/deg (n ϭ 11). By 8 days, thresholds reached 0.210 cyc/deg, where they remained until day 56. Thereafter, the thresholds begin to recover, and while they are near control values at 85 and 94 days PI, they still differ significantly (P Ͻ 0.05). At 105 and 119 (not shown) days PI, thresholds in injected eyes no longer differ from those in control values. Eleven rats were studied, initially in two groups (n ϭ 5 and 6, F and Ⅺ, respectively). These groups were examined on alternate days until day 21 PI; thereafter, the rats of both groups were examined at the same PI intervals. The spatial frequency thresholds at any given age are extremely consistent from animal to animal resulting in little variance, and therefore the error bars on the graph are hidden by the symbols of the data points.
Scotopic b-wave amplitudes remained below control values through 91 days PI, and were significantly different through 49 days and at 70 days PI (Fig. 1A) . Photopic b-waves were the most severely affected both in the degree and duration of suppression. These remained below control levels throughout the test period and were significantly different from those of controls through 84 days PI, except at 63 days PI. Thus, the first time when all three ERG waves recovered from CNTFinduced suppression was at 91 days PI.
Optokinetic Response. The spatial frequency threshold of the OKR averaged 0.53 cycles per degree (cyc/deg) before injection (Fig. 1B) , which was comparable to previously published values from the same strain. 30 PI measures revealed that thresholds through CNTF-injected eyes dropped slightly to 0.51 cyc/deg after 2 days, and by 3 days the thresholds had declined to 0.45 cyc/deg (Fig. 1B) , the first PI interval at which the thresholds were significantly different from those of controls (P Ͻ 0.001). This decline continued until day 8 when the threshold reached 0.21 cyc/deg where it remained until PI day 56. Thereafter, the threshold began to recover. The spatial frequency threshold had recovered to near control values by 85 and 94 days PI, but still differed significantly (P Ͻ 0.05). Full recovery was seen at 105 days (Fig. 1B) and beyond (data not shown).
Luminance Threshold Responses Measured in the Superior Colliculus. Multiunit recordings were made in five animals 2 weeks after intravitreous injection of CNTF in the right eye using the same doses as those used for the ERG and behavioral testing in the initial high-dose study. The left eye was an intact control. In each animal, the thresholds were measured at four to six points in each colliculus. In sum, we collected data from 29 points related to the injected eyes, and from 23 points related to the untreated eyes. The corresponding mean values (ϮSEM) of the thresholds were 0.64 Ϯ 0.085 log units for the injected eyes, and 0.29 Ϯ 0.023 log units for the untreated eyes. Thus, CNTF injection elevated the visual thresholds in treated eyes by 0.35 log units (ϳ2.2 times) in comparison with untreated eyes with a high level of statistical significance (P Ͻ 10 Ϫ6 ). Morphologic Changes. We examined the retinas of three or more rats before and 6, 21, 28, and 199 days after intravitreous injection of 10 g CNTF. At 6 days PI, the PR outer segments were clearly damaged, being irregular in caliber and somewhat tattered (Fig. 2B ) compared with the smooth profiles of normal outer segments (Fig. 2A) . The rod outer segments were also much shorter than normal, reduced to approximately 54% of their normal length (preinjection length, 23.6 Ϯ 1.1 m, mean Ϯ SD; 6 days PI, 12.7 Ϯ 0.8 m; n ϭ 3; P Ͻ 0.0005). By 21 days PI (Fig. 2C) and thereafter, the outer segments had returned to their normal appearance and length (preinjection 23.6 Ϯ 1.1 m; 21 days PI, 23.8 Ϯ 0.8 m, n ϭ 3, P ϭ 0.85). The outer segments were normal at the later ages, as well (data not shown). These changes are virtually identical with those reported by Wen et al. 27 at 6 and 21 days PI. The rod PR nuclei appeared normal at all PI times (Figs. 2B,  2C) , and at no time did they show dispersed heterochromatin, giving a conelike appearance such as that seen with continuous delivery of CNTF in mice 17 and rabbits.
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Dose-Response Analysis of Transient Changes Induced by Intravitreous Injection of CNTF. Persistent suppression of ERG responses and reduction of spatial frequency thresholds of the OKR resulted from injection of 10 g CNTF. Since the doses being tested for potential therapeutic use in humans are several orders of magnitude lower than the 10 g used in the present study and by Wen et al., 27 we performed a log-unit step reduction dose-response analysis of ERG responses and OKR threshold measurements at 6 and 21 days PI.
As already noted, the 10-g (10,000 ng) injection resulted in a large reduction in the OKR threshold and in all ERG responses 6 days PI, most of which had not returned to normal values at 21 days PI (Fig. 3A) . After a 1000-ng dose (Fig. 3B) , all the measured parameters were similarly affected at 6 days PI, but by 21 days PI, all three of the ERG responses had recovered to levels not significantly different from those of control eyes. The OKR threshold, while not as reduced as it was with the higher dose, nevertheless was still affected at 21 days PI (Fig.  3B ). At a dose of 100 ng (Fig. 3C) , the ERG responses at 6 days PI appeared somewhat reduced, but were not significantly different from control values, and by 21 days PI, all the ERG responses were at normal levels (Fig. 3C) . At doses of 10 ng (Fig. 3D) and 1 ng (Fig. 3E) , the ERG responses were unaffected by the CNTF injection.
The OKR thresholds were reduced at lower doses of CNTF than those affecting the ERG responses. At a dose of 1000 ng, for example, the OKR threshold was still reduced from normal at 21 days PI (Fig. 3B) , whereas the ERG responses no longer were significantly different from that of the control. Similarly, at both PI intervals at a dose of 100 ng (Fig. 3C ) and after 6 days PI at a dose of 10 ng (Fig. 3D) , OKR thresholds were still reduced, whereas the ERG responses were not different from control values. Neither OKR thresholds nor ERG responses were affected by the dose of 1 ng (Fig. 3E) .
Dose-Response Analysis of Protection of the Retina from Constant-Light Damage by Intravitreous Injection of CNTF. The injection of 100, 200, and 400 ng CNTF gave maximum protection from the damaging effects of a 7-day constant light exposure (Fig. 4) . The dose of 50 ng was slightly less protective, but was still significantly indistinguishable from that produced by 400 ng. The dose of 25 ng provided significantly less protection than the maximum dose (P Ͻ 0.005), but it gave a relative score of 2ϩ for the degree of protection (Fig.  4) , which is considered moderate protection. 45 Lower doses of 10, 2, and 0.2 ng gave progressively less rescue, but while the protection afforded by10-ng dose was minimal, it was significantly greater than that provided by the 0.2-ng dose (P Ͻ 0.05).
Effects of Subretinal AAV-CNTF Injection
Functional Changes Measured with the ERG. Rats injected subretinally with AAV-CNTF were examined by ERG at 42 and 95 days PI. As shown in Figure 5A , all ERG amplitudes were approximately 20% to 40% lower than in contralateral control eyes at 42 days PI and approximately 20% to 50% lower at 95 days PI, although at the latter PI interval, the scotopic 
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a-waves were not significantly different from control values. As with the intravitreous CNTF injections, the photopic b-waves were the most significantly depressed of the different ERG responses (Fig. 5A) . Optokinetic Response. Spatial frequency thresholds were obtained before injection, and all eyes tested returned normal values (0.53 cyc/deg, n ϭ 12). 30 Thresholds obtained after injection were very close to normal through 11 days PI (0.50 cyc/deg; Fig. 5B ) but were already significantly lower than normal by 11 days PI (P Ͻ 0.01). By 14 days PI, however, the thresholds had fallen rapidly to 0.390 cyc/deg (Fig. 5B) . The thresholds continued to decrease rapidly to 0.210 cyc/deg by 18 days to Ͻ50% of normal (P Ͻ 10 Ϫ10 ), where they remained unchanged until at least 180 days PI, the longest PI interval examined (Fig. 5B) .
A second group of animals with subretinal AAV-vectored CNTF was tested at 120 days PI and also showed a significant impairment in acuity (0.300 cyc/deg), although slightly less than the previous group (data not shown). Noninjected eyes of all rats had normal thresholds (0.53 cyc/deg) at all points tested.
Acuity. The perceptual visual acuity of five animals that received AAV-vectored CNTF was measured binocularly and monocularly through each eye separately at 6 months PI by using the VWT. All animals learned the task readily and had no obvious behavioral deficits in task performance. Acuity measured binocularly and monocularly from noninjected eyes was approximately 1.0 cyc/deg (Fig. 6) , which is comparable to previous data generated in Long-Evans rats. 32, 38, 40 However, acuity measured monocularly through the injected eye (Fig. 6 ) was significantly lower (0.500 cyc/deg, P Ͻ 0.003).
Morphologic Changes. A group of five rats that had been injected subretinally in the superior hemisphere with AAV-CNTF and that showed suppressed ERG amplitudes (Fig. 5A ) and reduced spatial frequency thresholds at 180 days PI (Fig.  5B) was examined histologically at 194 days PI. The retinas of two of the injected eyes appeared normal throughout the retinal section along the vertical meridian (cf. Figs. 7A, 7B; Fig.  8 ). However, three of the retinas showed loss of PRs across at least half of the superior hemisphere (Fig. 8) , with reduction of the ONL to one to three rows of nuclei (Figs. 7C, 8) . Despite the significant loss of PRs in some regions near the subretinal injections, the overall ONL thickness of the five injected eyes (23.8 Ϯ 2.6 m, mean Ϯ SEM) was only slightly less than that of noninjected controls (25.3 Ϯ 0.6 m) and did not differ significantly (P ϭ 0.16). Figure 1 (n ϭ 11); (B, C) 1000 and 100 ng, respectively (n ϭ 5). (D, E) 10 and 1 ng, respectively (n ϭ 3). The suppression of ERG amplitudes of all three waveforms is significant with 10,000 ng at 6 and 21 days PI, and at 6 days PI with 1000 ng, but not thereafter. A significant reduction in OKR thresholds occurs at even lower doses, at 6 days PI with 100 ng and with a very small reduction at 21 days PI with 100 ng, and 6 days PI with 10 ng. There was no measurable effect on the OKR thresholds at 21 days PI with 10 ng, or at either PI interval with 1 ng.
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IOVS, December 2007, Vol. 48, No. 12 Most of the PRs in the severely depleted areas of the ONL showed dispersed heterochromatin, giving them a conelike appearance, and these cells were also present in the transition zones between the most degenerated and normal regions of retina (Fig. 7D) . However, none were present in regions of relatively normal retina, such as that shown in Figure 7B or at the far right of Figure 7C .
Since continuous delivery of CNTF results in an increased thickness of the inner retina in dogs, 25 we measured the inner retina of the eyes injected with AAV-CNTF as we did for the ONL. The thickness of the inner retina in the eyes injected with AAV-CNTF was indistinguishable from that in the control eyes, regardless of whether the entire retina was compared from all five injected animals or from the three injected animals that showed loss of the ONL, measuring the INL only in the regions of the ONL loss (data not shown).
Using immunohistochemistry, Rhee et al. 26 have found that the same AAV-CNTF vector used in the present study causes an increase in the number and a change in the distribution of bipolar and Müller cell nuclei in the degenerating retinas of rds ϩ/ϪP216L transgenic mice. Although we could not use cellspecific staining with the plastic-embedded sections in the present study, we found changes in the inner nuclear layer of the normal rats injected with AAV-CNTF that were consistent with those found by Rhee et al., 26 at least for Müller cell nuclei that can be identified in plastic sections. Whereas most Müller cell nuclei in normal rat retinas are situated in the middle or middle-to-outer part of the INL (Fig. 7A ), many were found distributed throughout the INL, both in regions of otherwise normal retina (Fig. 7B ) and in partially degenerated regions (Fig. 7C) .
DISCUSSION
We found that intravitreous injection of a high dose of CNTF (10 g) results not only in transient suppression of ERG responses, but also functional changes in vision in normal rats as demonstrated by transient reduction of OKR thresholds and reduction of luminance threshold responses measured in the superior colliculus. In addition, continuous delivery of AAVvectored CNTF results in sustained reduction in ERG responses and OKR thresholds for at least 6 months, as well as reduced visual acuity measured with the VWT.
The precision with which the decline in OKR thresholds paralleled the suppression of the ERG responses after CNTF injection (Fig. 1) was remarkable, and although the ERG responses showed a more rapid partial recovery than did the spatial frequency thresholds, both returned to normal at about the same time, 91 (for all ERG responses) and 105 days after injection, respectively. The reduction in spatial frequency thresholds after subretinal AAV-CNTF injection occurred between 11 and 18 days after injection, which is precisely the time required for full gene expression of AAV2-vectored markers such as green fluorescent protein. 46 Thus, the OKR can be FIGURE 4. Dose-response analysis of protection of the retina of albino Sprague-Dawley rats from constant light damage due to intravitreous injection of rat CNTF. CNTF was injected 2 days before a 7-day exposure to light. Doses of 50, 100, and 200 ng were not significantly different from the highest dose of 400 ng, and thus all gave maximum protection. A dose of 25 ng gave moderate protection, but was significantly less effective than the maximum dose (P Ͻ 0.005). Doses of 10 ng and lower gave progressively less protection, but protection from the 10-ng dose was significantly greater than the 0.2-ng dose (P Ͻ 0.05). For each dose, n ϭ 5 or 6. The thresholds of the injected eyes appeared almost normal until 11 days PI, although they were already significantly lower than normal (P Ͻ 0.01) and dropped rapidly between 11 and 18 days PI, after which they remained consistently at approximately 0.210 to 0.233 cyc/deg for up to 180 days PI. The measurements up to 49 days PI are from a group of nine rats, and the measurements at 180 days are from five different rats. At 18 days PI and thereafter, the injected eyes differed from control values significantly (P Ͻ 10 Ϫ10 ).
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used with high precision and sensitivity to rapidly and noninvasively assess the positive and negative effects of vision-based therapies. CNTF signaling involves binding of the cytokine to receptor-associated Jak kinases, leading to phosphorylation of members of the signal transducer and activator of transcription (STAT) family, STAT1 and -3, as well as the triggering of signal-related kinase (p42/44 ERK). 47, 48 When the same AAV-CNTF used in the present study was injected subretinally into transgenic rds ϩ/ϪP216L mice, persistent cytokine signaling was seen 65 days later in the retina, as elevated levels of phospho-STAT1 and -3 and phospho-ERK1 and -2 were demonstrated by immunocytochemical staining and Western blot analyses. 26 Moreover, Bok et al. 17 have shown in these same mice that all ERG responses were significantly and persistently reduced after AAV-CNTF injection. Thus, in the present study, it was not surprising to find persistent ERG and visual behavioral changes in the rats injected with AAV-CNTF. However, it was most unexpected to find an extremely long recovery time of 91 to 105 days after intravitreous injection of CNTF, particularly since previous studies have shown CNTF to be cleared from the retina between 2 and 4 days 47, 49 and only transient elevation of relevant signaling molecules. After intravitreous injection of CNTF, pERK is elevated for less than 6 hours, 50 STAT1 and -3 phosphorylation signals are seen for only up to 4 days, 47 and phosphorylated MAPK (a member of the ras-MAPK signaling pathway) was only activated at 1 hour in rats. 47 With the same high dose (10 g) of intravitreously injected CNTF that we used, Wen et al. 27 found an increase in STAT3 phosphorylation for as long as 6 days, with a gross reduction by 3 weeks, far less than the recovery time for the ERG and OKR (Fig. 1) . In each of these and other studies and in studies showing that CNTF receptors are localized primarily on Müller cells and not on PRs in rodents, 51 it is strongly suggested that Müller cells are the target of CNTF in the retina and that these cells initiate neuroprotective signaling of undetermined nature. 27, 47 This same undefined and perhaps long-lived signal may also mediate the suppression of ERG responses and spatial frequency thresholds and be responsible for the long recovery time after CNTF injection, but this remains to be determined.
There is an apparent dose dependence of the PR nuclear phenotypic changes caused by subretinally injected AAV-CNTF. Only those regions near the injection site, which were presumably exposed to the highest concentration of continuous CNTF, showed rod PR nuclei with dispersed heterochromatin, which may signal structural modification of DNA during gene expression. 52 Indeed, it was only in the areas where there was frank loss of some PR cells that the nuclear changes in the surviving cells were seen, yet we are fairly certain based on other studies of subretinal AAV injections that some secreted CNTF was available to all PRs. 17 Similar dose-dependence for CNTF-induced changes in nuclear phenotype and other features have been found in rds ϩ/ϪP216L mice by comparison of results from different vectors, promoters, and routes of administration 17 and in normal rabbits 24 and normal and rcd-1 dogs, 25 where different concentrations of CNTF were delivered by encapsulated cell-based technology. Thus, in the normal Long-Evans rat, we see that AAV-vectored CNTF may cause PR cell death at the area of highest concentration, yet cause no structural damage to PRs adjacent to the area of highest concentration. Liang et al. (IOVS 2003; 44 :ARVO E-Abstract 3585) have made preliminary observations with intravitreous injections of AAV-CNTF in albino Sprague-Dawley rats, with some PR cell death in 5 of 9 rats, primarily in the retinal quadrant that was injected, again showing a dose-dependent negative effect. The exact cause of cell death is not known. We assume it is due to the highly localized and continuous release of CNTF after the subretinal injection of AAV-CNTF and not to the AAV vector itself. This same AAV vector has been injected subretinally to deliver DNA that encodes a number of different molecules without causing PR degeneration. 44, 53, 54 On the other hand, at very high doses greater than used in our study, highly localized PR damage has been reported. 55, 56 Moreover, we cannot exclude the possibility that the subretinal injection in some way changes the sensitivity of PRs to the effects of AAV-vectored CNTF.
The effects of a high dose of CNTF on the ERG and behavioral responses are greater for the cone pathways, or the cones themselves, than for the rods. In the present study, behavioral testing with the VOS and VWT is in the photopic illuminance range (30 -40 cd/m 2 ), and the photopic b-wave showed the greatest and longest suppression after a high-dose CNTF injection. The photopic b-wave ERG response reflects cone function, but is thought to be generated primarily by depolarizing bipolar cells in the rat. 57 Consistent with our findings with the high CNTF dose, in normal rabbits the only suppressed ERG responses found with continuously released CNTF using encapsulated cell technology 20 were those of cone b-waves at dim flash intensities. 24 The cones themselves may actually be affected by CNTF (albeit perhaps indirectly). In rcd-1 and normal dog retinas, higher doses of CNTF released from encapsulated cells resulted in reduced immunohistochemical staining with antibody to human cone arrestin, and the effect was greater than that on rhodopsin (in rods). 25 Similarly, in AAV-vectored CNTF in rds ϩ/ϪP216L mouse retinas, both s-and m-opsin normally expressed in cones was greatly reduced, but rhodopsin expression was not significantly affected. 26 It should be noted that AAV-vectored CNTF also results in the increase in number and distribution of bipolar and Müller cell nuclei in rds ϩ/ϪP216L mouse retinas, 26 and we found similar changes in the distribution of Müller cell nuclei in normal rat retinas in the present study with the same AAV-CNTF vector. Even single injections of CNTF can cause similar (or even more extensive) cellular changes in the immature retina of XLPRA2 dogs.
58 FIGURE 6. Change in perceptual visual acuity measured using the visual water task 6 months after subretinal injection of AAV-CNTF. Animals measured binocularly showed acuity of approximately 1.0 cyc/deg, normal for pigmented rats. Similarly, acuity measured monocularly through the noninjected control eye was the same as that measured binocularly, whereas the acuity measured through the eyes injected with AAV-CNTF was reduced to approximately half that of normal eyes (P Ͻ 0.003).
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IOVS, December 2007, Vol. 48, No. 12 We have performed a formal dose-response study of intravitreously injected CNTF (Fig. 3) , and the results were instructive in several ways. First, unlike the high (10,000 ng) dose, it was apparent that the ERG suppression was transient and short lived at a dose of 1,000 ng, and that none of the ERG waves was suppressed at doses of 100 ng or less. Second, the study demonstrated a clear segregation of the effect of CNTF on the ERG and OKR. The OKR was more sensitive to the effects of CNTF than was the ERG, with significant reduction in spatial frequency thresholds of the OKR at a 1-to 2-log-unit lower dose than that affecting the ERG. This greater effect on the OKR in the dose-response study is consistent with that seen with the very high dose (Fig. 1) , in which the OKR thresholds remained at a very low level for a prolonged period, whereas the ERG responses partially recovered sooner. The separation of ERG responses and OKR thresholds after CNTF injection indicates that the two measures may not be tightly linked, but the mechanisms for this remain to be explored.
Third, the dose-response study provides a possible explanation of the prolonged recovery time after high-dose CNTF injection compared with the full recovery seen by 21 days by Wen et al. 27 We have used recombinant rat CNTF rather than recombinant human CNTF used by Wen et al., and rat CNTF has four to five times the potency in survival-promoting activity than the human form. 59 In our present study, reduction of CNTF dose by 1 log unit (to 1000 ng) resulted in full recovery 
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of ERG responses at 21 days PI, just as seen by Wen et al. 27 It should be pointed out that structurally, our findings of rod outer segment recovery to normal length by 21 days PI are the same as those of Wen et al.
Fourth, comparison of the dose-response findings with a dose-response study of light damage strongly suggests that therapeutic doses of CNTF exist that do not suppress ERG responses. In the light-damage study, a dose of 10 ng provided minimal but significant protection, 25 ng gave moderate protection, and 50 and 100 ng gave strong protection (Fig. 4) , and none of these doses suppressed the ERG responses (Fig. 3) . It should be noted that two different rat strains were compared, but this difference is unavoidable since albinos must be used for light-damage studies and pigmented rats must be used to obtain consistent OKR thresholds (Prusky GT, unpublished observations, 2004) . Our findings support the observation by Bush et al. 24 that doses of CNTF released by encapsulated cell technology that protect PRs in a canine model do not adversely affect the ERG in normal rabbits. The only other dose-response study of any neurotrophic factor in the eye, as far as we are aware, was performed in the rcd-1 dog with RD, 20 and in that case the most protective doses were accompanied by morphologic changes in the retina. 25 It should be noted that in the present study, the more sensitive OKR thresholds were still slightly reduced at therapeutic doses of 100 ng at 21 days PI and 10 ng at 6 days PI, but these effects were extremely small. The significance of these small reductions is unclear.
The fact that CNTF is neuroprotective in many forms of RD in laboratory animals provided the impetus, in part, to a phase I clinical trial of CNTF delivered by encapsulated cell intraocular implants in patients with retinitis pigmentosa that was successfully completed recently. 22 What consequences do the present findings have for clinical application of CNTF? Precise applicability of our findings to human retinas must be qualified for several reasons. First, accurate dose comparisons are difficult to make. The doses released in the first human trial with encapsulated cell devices were approximately 0.28 ng/d at 6 months after implantation with the lower-dose device, and 1.53 ng/d at 6 months with the higher-dose device. 22 On the one hand, these doses are probably below the threshold for ERG suppression, even in the present study, but in addition, these doses in the human trials were diluted approximately 200 times more than in the rat eye due to differences in eye size (vitreous volume approximately 4 mL in human eye, 20 L in rat eye). Moreover, rat CNTF was used in the present study, which is four to five times more potent than human CNTF 59 in the clinical trial. On the other hand, the CNTF in the human trials is released continuously, and the consequences of even low-dose continuous release is difficult to assess. Second, there are species differences reported in the localization of CNTFR␣ to PR cells, and rodent retinas may differ from human retinas in this regard. 51 Third, it is probable that degenerating PR cells respond differently to various agents than do normal PRs. Zeiss et al. 25 found that continuous application of CNTF caused greater morphological alterations in rcd-1 dog retinas than in wild-type dog retinas. However, although AAV-vectored CNTF suppresses ERG responses in wild-type mouse retinas, 23 we have found that the same AAV-CNTF vector used in the present study can cause overt PR degeneration in the same strain (C57BL/6) of wild-type mice in the region of injection (and presumably highest concentration of CNTF; LaVail MM et al., unpublished observations, 2004). The same vector never resulted in this cell loss in rds ϩ/ϪP216L mouse retinas, 17 adding further to the idea that normal retinas may be more sensitive to the negative effects of high doses of CNTF than are degenerating retinas. Fourth, in the recent human clinical trial, in contrast to our findings several patients receiving CNTF-releasing implants actually showed improved visual acuity that was maintained for 6 months after the trial. 22 Thus, there is still much to learn about the protective and possible negative actions of CNTF and how they relate to retinas undergoing inherited RDs. It is clear that very high doses of CNTF applied to the retina can cause reduction in ERG response amplitudes, elevation of luminance thresholds as measured at the superior colliculus, reduction in visual acuity and behavioral tracking responses and, in some cases, outright loss of PRs. Thus, therapeutic application of CNTF in RDs should be closely monitored to prevent these negative effects, should they occur in the human retina. However, our doseresponse studies strongly support the notion that therapeutic doses of CNTF exist that do not suppress ERG responses. 
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